Overview

Dose-Escalation Study in Advanced Colon Cancer Patients

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
This study is exploring different administration schedules (short versus prolonged infusion) to optimize the safety and efficacy profile of EPO906A (patupilone) in patients with pretreated advanced colon cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Epothilone B